• Publications
  • Archives
  • BCIQ
  • Conferences
  • Free Trial / Subscribe
  • Sign In
  • English
  • 简体中文
  • 日本語
  • 한국어
Biocentury

// BCIQ

Menu Menu
  • Home Today
  • Publications Publications
    • Publications Home
    • BioCentury
    • BC Innovations
    • BC Extra
    • BC Week In Review
    • Current Issues
  • Archives Archives
    • Archives Home
    • Basic Search
    • Advanced Search
    • Back Issues
  • BCIQ BCIQ
    • BCIQ Home
    • Overview
    • Newsfeed
    • Companies
    • Products
    • Finance
    • Deals
  • Conferences Conferences
    • Conferences Home
    • Newsmakers
    • Bio€quity Europe
    • Future Leaders
    • China Healthcare Summit
    • Other Industry Events
  • eLearning Interact
    • eLearning Home
    • Videos
    • White Papers
    • Follow Us

      Twitter LinkedIn RSS

X
  • Newsfeed
  • Companies
  • Products
  • Finance
  • Deals
  • Profile Reports
  • Overview
  • Pipeline
  • Deals
  • Financings
  • Earnings Summary
  • Stock Summary
  • Articles

1 documents

  • BC Week In Review 1
    • Clinical News 1
      • Regulatory 1
Read All
20:19 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Positive CHMP vote likely for Clovis' PARP inhibitor

Clovis Oncology Inc. (NASDAQ:CLVS) said EMA's CHMP communicated a "positive trend vote" for an MAA for rucaparib (CO-338) to treat platinum-sensitive, BRCA-mutant advanced ovarian cancer. Clovis expects a formal vote on the MAA at CHMP's...
Read More
About Biocentury
  • Company Overview
  • Management
  • Editorial & Research
  • Market data
Contact
  • Contact Us
  • Advertising & Sponsorship
  • Career Opportunities
Support
  • Customer Service
  • Reprints
  • FAQs
Products & Solutions
  • Products Overview
  • Publications
  • Archives
  • BCIQ
  • Conferences
  • eLearning
  • RSS Feeds
Legal
  • User Agreement
  • Terms of Use
  • Privacy Policy
  • Your California Privacy Rights
  • Use of Images
  • Market data
  • Follow Us

    Twitter LinkedIn RSS

© 2018 BioCentury Inc. All Rights Reserved.    Terms & Conditions | Privacy Policy